VDPHL01 Hair Loss Pills: How the New Drug Works and When It Will Be Available

Male pattern baldness has been defeated—the American company Veradermics has developed a minoxidil pill that dramatically boosts hair growth without side effects.  More than 530 men took the drug VDPHL01, and their hair began growing noticeably—by the second month, the increase had reached 36.4 hairs per 1 cm². And all this came without any serious side effects. If the FDA approves the drug, it will go on sale to anyone interested worldwide.

The American biotechnology company Veradermics has found itself at the center of attention in the pharmaceutical market and medical community. The reason is its experimental drug VDPHL01 — the first pill for male pattern baldness in nearly thirty years to be headed for approval by the U.S. regulator, the FDA. Results from large-scale Phase 3 clinical trials showed that the drug produces rapid, dense hair growth without causing dangerous cardiovascular side effects. Against this backdrop, Veradermics shares surged 567% after February 2026, making the company one of the year's most successful stock market debuts.

Androgenetic alopecia affects a vast number of people—around 80 million in the U.S. alone, including 50 million men and 30 million women. However, regulators have not approved any new oral treatments for the condition since the late 1990s. The main treatment in use remained minoxidil, which has an unusual history. Oral minoxidil was first approved by the FDA in 1979 as a treatment for severe hypertension. It was later discovered to stimulate hair follicles, leading to its use in lotions and foams (sold under the brand name Rogaine), as well as orally off-label.

Topical minoxidil has significant drawbacks: up to 86% of patients eventually discontinue treatment due to the need for daily application and its modest efficacy, as only a small proportion of the active ingredient reaches the follicle. Standard immediate-release minoxidil tablets are more potent, but cause a sharp spike in the drug's plasma concentration. This creates a significant risk of cardiovascular complications — such as a drop in blood pressure, tachycardia, and edema, which imposes a strict limit on safe dosing.

Veradermics researchers, led by dermatologist and company CEO Reid Waldman, focused on a biochemical aspect of how the active ingredient works. Minoxidil itself does not act directly on the hair follicle. Follicular tissue contains the enzyme SULT1A1 (sulfotransferase), which converts minoxidil into its active form—minoxidil sulfate. The SULT1A1 enzyme has limited processing capacity and works over time. When a conventional tablet is taken, the sudden spike in the substance's concentration overwhelms the enzyme, causing most of the drug to go to waste while still exerting toxic effects on the cardiovascular system.

To solve this problem, Veradermics developed VDPHL01, an extended-release tablet based on a hydrogel matrix. It releases minoxidil steadily over 12 hours. This pharmacokinetic profile smooths out peak blood concentrations, keeping them below the dangerous cardiovascular threshold of 20 ng/mL while maintaining levels above the 1.62 ng/mL required to activate hair growth for twice as long.

The concept's efficacy was confirmed by two pivotal clinical trials— Study 302 and Study 304, involving more than 1,000 men aged 18 to 65 with mild to moderate alopecia. In Study 302, participants taking VDPHL01 at a dose of 8.5 mg once or twice daily had an average increase in target-area hair density of 30.3 and 33.0 hairs per square centimeter, respectively, after six months, compared with 7.3 in the placebo group. In Study 304, the corresponding increases were 28.6 and 36.4 hairs per square centimeter, compared with 6.6 for placebo. The first statistically significant results were recorded just two months after treatment began.

Опросы самих участников по шкале AAIRS показали, что до 86% пациентов отметили визуальное улучшение покрова, а до 68,7% охарактеризовали изменения как “улучшение” или “значительное улучшение”. При этом у пациентов не зафиксировано ни одного серьезного нежелательного явления кардиогенного характера. Побочные эффекты ограничились легкими периферическими отеками (2,8–4,5%) и гипертрихозом — появлением пушковых волос на других участках тела (2,2–9,0%). Параллельно компанией проводятся испытания для женщин: фаза 2 (Study 207) показала прирост 22,7–23,3 волоса на квадратный сантиметр, а результаты третьей фазы (Study 306) с участием 556 женщин ожидаются в первой половине 2027 года. В случае одобрения VDPHL01 станет первым пероральным препаратом от облысения, официально разрешенным для женщин.

Успешные испытания вызвали огромный резонанс на Уолл-стрит. Рыночные аналитики отмечают, что динамика акций Veradermics обогнала такие громкие размещения, как SpaceX и Cerebras Systems, а привлеченное пост-IPO финансирование в $472 миллиона вошло в число крупнейших в секторе. Мировой рынок средств от алопеции к 2028 году может превысить 30 миллиардов долларов, и около 91% опрошенных дерматологов уже заявили о готовности назначать новый препарат. В то же время бизнес Veradermics остается рискованным: убытки компании за второй квартал 2026 года выросли до 23,5 миллионов долларов из-за расходов на клинические тесты, а все благополучие фирмы зависит от единственной разработки. Тем не менее, патентная защита VDPHL01 действует минимум до 2043 года, а эксперты сравнивают потенциальный потребительский ажиотаж вокруг таблеток от облысения со сдвигом, который произвели на рынке препараты для снижения веса.